Frank Stegelmann

4.5k total citations
37 papers, 619 citations indexed

About

Frank Stegelmann is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Frank Stegelmann has authored 37 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 32 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Frank Stegelmann's work include Chronic Myeloid Leukemia Treatments (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers) and Acute Myeloid Leukemia Research (14 papers). Frank Stegelmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (27 papers) and Acute Myeloid Leukemia Research (14 papers). Frank Stegelmann collaborates with scholars based in Germany, United Kingdom and Italy. Frank Stegelmann's co-authors include Konstanze Döhner, Steffen Stenger, Robert L. Modlin, Nicholas C.P. Cross, Joannah Score, Thomas Ernst, Nils Winkelmann, Claire Hidalgo-Curtis, Amy V. Jones and Daniel Ward and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Frank Stegelmann

33 papers receiving 613 citations

Peers

Frank Stegelmann

HEMAT

GENET

RHEUM

Abhay Patki United States

Árpád Bátai Hungary

Franck‐Emmanuel Nicolini France

Hirotoshi Sakaguchi Japan

Jess F. Peterson United States

Evgeny Klyuchnikov Germany

Stéphane Prost France

Rudolf Peceny Germany

Yvonne Suessmuth United States

Evelyne D’Incan France

Abhay Patki United States

Frank Stegelmann

234 ×0.7

235 ×0.8

HEMAT

307 ×1.0

GENET

131 ×1.0

RHEUM

129 ×1.3

Citations per year, relative to Frank Stegelmann Frank Stegelmann (= 1×) peers Abhay Patki

Countries citing papers authored by Frank Stegelmann

Since Specialization

Citations

This map shows the geographic impact of Frank Stegelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Stegelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Stegelmann more than expected).

Fields of papers citing papers by Frank Stegelmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Stegelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Stegelmann. The network helps show where Frank Stegelmann may publish in the future.

Co-authorship network of co-authors of Frank Stegelmann

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Stegelmann. A scholar is included among the top collaborators of Frank Stegelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Stegelmann. Frank Stegelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coutre, Philipp le, Andreas Burchert, Susanne Saußele, et al.. (2025). Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trial. Acta Haematologica. 1–13.

Krumbholz, Manuela, Anna Dolnik, Eric Sträng, et al.. (2024). A high proportion of germline variants in pediatric chronic myeloid leukemia. Molecular Cancer. 23(1). 206–206. 4 indexed citations

Jilg, Stefanie, Juliana Schwaab, Katja Sockel, et al.. (2024). MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Annals of Hematology. 103(10). 4065–4077. 1 indexed citations

Stegelmann, Frank, Lino L. Teichmann, Florian H. Heidel, et al.. (2023). Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Leukemia. 37(4). 924–928. 5 indexed citations

Saußele, Susanne, Paul La Rosée, Alexander Kiani, et al.. (2023). Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia. Acta Haematologica. 147(3). 344–351. 1 indexed citations

Grießhammer, Martin, Kai Wille, Parvis Sadjadian, Frank Stegelmann, & Konstanze Döhner. (2021). A review of hydroxyurea-related cutaneous adverse events. Expert Opinion on Drug Safety. 20(12). 1515–1521. 7 indexed citations

Stegelmann, Frank, Kai Wille, Christiane Fuchs, et al.. (2020). Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia. 35(2). 628–631. 9 indexed citations

Saußele, Susanne, Wilhelm Haverkamp, Fabian Lang, et al.. (2019). Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematologica. 143(3). 217–231. 33 indexed citations

Stegelmann, Frank, Steffen Koschmieder, Susanne Isfort, et al.. (2019). S1608 RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG‐0212 COMBINATION TRIAL (NCT01644110). HemaSphere. 3(S1). 740–741. 7 indexed citations

10.

Hochhaus, Andreas, Susanne Saußele, Gabriela M. Baerlocher, et al.. (2018). Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. Blood. 132(Supplement 1). 460–460. 3 indexed citations

11.

Stegelmann, Frank, Martin Grießhammer, Markus Bangerter, et al.. (2017). COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110). Haematologica. 102. 280–280. 2 indexed citations

12.

Schlenk, Richard F., Frank Stegelmann, Andreas Reiter, et al.. (2016). Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 31(4). 889–895. 14 indexed citations

13.

Stegelmann, Frank, Markus Bangerter, Florian H. Heidel, et al.. (2015). A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. Blood. 126(23). 826–826. 8 indexed citations

14.

Jutzi, Jonas S., Ruzhica Bogeska, Gorica Nikoloski, et al.. (2013). MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. The Journal of Experimental Medicine. 210(5). 1003–1019. 49 indexed citations

15.

Godfrey, Anna L., Edwin Chen, Francesca Pagano, et al.. (2012). JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 120(13). 2704–2707. 68 indexed citations

16.

Score, Joannah, Claire Hidalgo-Curtis, Amy V. Jones, et al.. (2011). Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood. 119(5). 1208–1213. 125 indexed citations

17.

Beer, Philip, Christina A. Ortmann, Frank Stegelmann, et al.. (2010). Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica. 95(12). 2153–2156. 17 indexed citations

18.

Stegelmann, Frank, Lars Bullinger, Martin Grießhammer, et al.. (2009). High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica. 95(4). 666–669. 35 indexed citations

19.

Stegelmann, Frank, H. M. Kvasnicka, & Martin Grießhammer. (2008). Chronische myeloproliferative Erkrankungen. 3(2). 24–32.

20.

Stegelmann, Frank, Max Bastian, Rauf Bhat, et al.. (2005). Coordinate Expression of CC Chemokine Ligand 5, Granulysin, and Perforin in CD8+ T Cells Provides a Host Defense Mechanism against Mycobacterium tuberculosis. The Journal of Immunology. 175(11). 7474–7483. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact